Individuals with comorbidities in addition to chronic obstructive pulmonary disease (COPD) have an elevated risk of exacerbations, more so if the comorbidity is another chronic respiratory disease, according to a study from the Netherlands.
Patients with chronic obstructive pulmonary disease (COPD) commonly experience acute exacerbations, which are most commonly triggered by viruses. Prompt and effective treatment is required to reduce the rate of exacerbations and this affects disease progression. Studies showed that long-acting muscarinic antagonists (LAMAs) and/or long-acting β2-agonists (LABAs) are safer than inhaled corticosteroids (ICS) for long-term use. At the Autumn Respiratory Seminar 2016, Professor Wisia Wedzicha of Imperial College, London, UK, discussed the results of LABA/LAMA therapy trials and the efficacy of indacaterol in combination with glycopyrronium (Ultibro®, Novartis) in reducing COPD exacerbations.
Prompt and effective treatment strategies for patients with chronic obstructive pulmonary disease (COPD) are crucial to improve outcomes. At the Autumn Respiratory Seminar 2016 in Hong Kong, Professor Andrew McIvor of the Firestone Institute for Respiratory Health, St. Joseph's Healthcare in Ontario, Canada, highlighted the importance of optimizing the use of a long-acting β2-agonist (LABA) with a long-acting muscarinic antagonist (LAMA), the continued role of LABA with inhaled corticosteroids (ICS) in preventing exacerbations, and the emerging role of the oral phosphodiesterase 4 (PDE4) inhibitor roflumilast in patients with COPD.